Semaglutide is a GLP-1 receptor agonist, a type of medication originally developed to regulate blood glucose levels in individuals with type 2 diabetes
Key protective strategies include: Pre-treatment ophthalmologic evaluation : Establish baseline retinal status before initiating GLP-1 therapy, particularly in patients with diabetes duration exceeding 10 years or poor prior glycemic control Individualized medication titration : Consider a more gradual dose escalation approach to avoid precipitous drops in blood glucose for patients with advanced diabetic retinopathy, in coordination with ophthalmology care Appropriate monitoring : Discuss with your healthcare provider whether more frequent eye examinations are needed based on your individual risk factors and baseline retinal status Prompt reporting of visual symptoms : Contact your healthcare provider immediately if you experience sudden vision loss, new or dense floaters, flashing lights, a "curtain" over your vision, eye pain with vision changes, or any sudden vision disturbance Patients without pre-existing diabetic retinopathy can generally follow standard eye examination schedules and do not require additional ophthalmologic monitoring solely due to GLP-1 use
Timing and Dosage Taking glutathione on an empty stomach can improve absorption
Sex, body mass index, and dietary fiber intake influence the human gut microbiome
The survival rate at 6-month, 12-month and 2 years was 82%, 54% and 26% in the group of patients treated only with TACE, while in the TACE+MEL group it was 100%, 68% and 40% of all patients, respectively
From the first consultation, we assess whether your medical records support causation, ensure your case aligns with the mass tort framework, and guide you through every stage
